Head-to-head · WeighScore
Auren Rx vs NuBloom
The verdict
Auren Rx takes it — 72.9/100 to 69/100.
Auren Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Auren Rx charges the same $149 for semaglutide and tirzepatide, which removes the usual reason to start on the weaker molecule.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Auren Rx | NuBloom |
|---|---|---|
| WeighScore | 72.9/100 | 69/100 |
| Grade | C | C |
| Scorecard rank | #79 | #144 |
| Semaglutide | $149/mo (auto-refill; a single month with no commitment is $179) | $149/mo (2.4 mg dose, compounded) |
| Tirzepatide | $149/mo (auto-refill; a single month with no commitment is $179) | $279/mo (15 mg dose, compounded) |
| Coverage | All 50 states | 49 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #79 · C
Strengths
- Semaglutide and tirzepatide cost the same, so the choice of molecule is clinical rather than budgetary
- A microdose lane is priced separately at $129 on auto-refill rather than folded into the standard figure
- Names its dispensing pharmacy, VialsRX, with a street address and a phone number in Houston, Texas
- Names a prescribing physician and practice, and publishes support hours of Monday to Friday, 9 AM to 6 PM Eastern
Where it loses points
- The $149 figure requires enrolling in auto-refill; a single month with no commitment is $179
- Two different medical groups are named for the same service — Wasef Health, PC on the contact page and FAQ, Beluga Health, P.A. in the telehealth consent
- Product pages advertise a free online visit while the Terms make the initial online visit and any laboratory testing the patient's responsibility
- The FAQ says all 50 states, the Terms say service is available only in certain states, and no list is published
- No compounding class is stated for VialsRX, so whether it operates under 503A or 503B is unknown
- NAD+ is priced at two different figures on the same site, which is not reassuring about the GLP-1 numbers
Graded #144 · C
Strengths
- Transparent, openly published pricing: compounded semaglutide $149/mo and tirzepatide $279/mo as flexible month-to-month subscriptions
- Founded and medically led by a named physician (Dr. Marianne Pinkston Mueller, family/integrative medicine, 25+ years)
- Whole-person model pairs GLP-1s with hormone, gut-health and longevity care plus in-depth lab testing
- State coverage published openly: 49 states listed on the site (all except Mississippi)
- Optional 90-day 1:1 coaching program with weekly meetings and unlimited text support ($599/mo)
Where it loses points
- Compounding pharmacy partners are not named anywhere on the site — a transparency gap
- NuBloom's own LegitScript/PCAB status is not displayed; only its telehealth partner is certified
- Compounded medications are not FDA-approved; one FAQ loosely calls them 'FDA-approved,' contradicting the product pages
- All sales are final and medical consult fees are non-refundable; no returns on prescription products
- Disputes go to binding individual arbitration; the Terms' governing-law state is left as an unfilled '[STATE]' placeholder
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 536 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.